Metronidazole-induced hepatotoxicity in a patient with xeroderma pigmentosum: A case report

Medicine (Baltimore). 2022 May 27;101(21):e29416. doi: 10.1097/MD.0000000000029416.

Abstract

Rationale: Whereas metronidazole-induced hepatotoxicity is quite rare in the general population, in individuals carrying a nucleotide excision repair disorder, namely Cockayne syndrome, there is a high risk of developing this complication.

Patient concerns: We report the case of a 44-year-old man, affected by xeroderma pigmentosum, who was admitted to the hospital presenting aspiration pneumoniae caused by worsening dysphagia and with severe hepatotoxicity during the hospitalization.

Diagnoses: Acute hepatitis, which was leading to acute liver failure, occurred during antibiotic treatment with metronidazole and ceftazidime with an elevation of liver enzymes consistent with hepatocellular damage pattern.

Interventions: Hydration with glucose 5% solution, pantoprazole and vitamin K were administered, meanwhile other causes of hepatitis were ruled out and the ongoing antibiotic treatment was stopped suspecting a drug-induced liver injury.

Outcomes: Liver function nearly completely recovered 1 month later with a first rapid improvement, within few days, of aminotransferases and coagulation studies, and slower of cholestatic enzymes.

Lessons: We describe the first case available in the literature of hepatotoxicity associated with metronidazole treatment in a xeroderma pigmentosum patient. Clinicians therefore, based on this report and according to the possible underlying mechanism shared by other genetic diseases characterized by alterations in the pathway of DNA-repair, should consider such adverse event also in patients affected by this rare disease.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Bacterial Agents
  • Chemical and Drug Induced Liver Injury* / complications
  • DNA Repair
  • Humans
  • Male
  • Metronidazole / adverse effects
  • Xeroderma Pigmentosum* / genetics

Substances

  • Anti-Bacterial Agents
  • Metronidazole